Walmart is set to join the Nasdaq-100 Index, replacing British pharmaceutical giant AstraZeneca, as part of an index rebalancing effective before the market opens on January 20, according to a statement released by Nasdaq. This move follows Walmart’s earlier announcement in November that it would shift its primary stock listing from the New York Stock Exchange (NYSE) to Nasdaq, marking a significant change for the world’s largest retailer after decades on the NYSE.
The inclusion of Walmart in the Nasdaq-100 Index underscores the growing appeal of Nasdaq as a listing venue for large, high-profile companies. The Nasdaq-100 Index tracks 100 of the most valuable non-financial companies listed on the Nasdaq exchange and includes global leaders such as Apple, Nvidia, Microsoft, and Amazon. In addition to the main index, Walmart will also be added to the Nasdaq-100 Equal Weighted Index and the Nasdaq-100 Ex-Tech Sector Index, further expanding its presence across Nasdaq’s flagship benchmarks.
Companies often decide to change listing venues when they believe another exchange offers better alignment with their investor base, advanced trading technology, enhanced services, or lower listing and compliance costs. In recent years, Nasdaq has positioned itself as an attractive platform not only for technology companies but also for major consumer, healthcare, and industrial firms seeking broader exposure and index inclusion.
Several companies that moved from the NYSE to Nasdaq in 2025 cited the growing prestige and visibility of the Nasdaq-100 Index as a key factor in their decision. Being part of the index can lead to increased demand from index-tracking funds and institutional investors, potentially boosting liquidity and long-term shareholder value.
For Walmart, the transition represents more than a symbolic shift. It aligns the retail giant with a group of globally influential companies and reflects its evolving business model, which increasingly integrates e-commerce, technology, and data-driven operations. Meanwhile, AstraZeneca’s removal highlights the competitive and dynamic nature of major stock indices, where changes in market capitalization and listings can quickly reshape index composition.


Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 



